Date: 2017-05-23
Type of information: Collaboration agreement
Compound: value-based payment reform models for gene therapies and other innovative treatments
Company: Bluebird bio (USA - MA) Duke University (USA - NC) Value-Based-Payment-Consortium
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details:
- • On May 23, 2017, bluebird bio announced that it will participate in a consortium led by Duke University’s Robert J. Margolis, MD, Center for Health Policy to develop a broadly-supported path for value-based payment reform models for gene therapies and other innovative treatments.
- The consortium – composed of patient advocates, payers, manufacturers, and providers, as well as experts in regulatory science, law, and policy – will collaborate to outline a path forward for payment reform involving innovative therapies, including genomic medicines for rare diseases.
- The initial phase of the project is expected to be completed in 2017. A white paper has already been published to provide background on value-based reimbursement for medical products.
Financial terms:
Latest news:
Is general: Yes
